Phathom to Host VOQUEZNA Theater and 3 Posters at DDW 2026
Phathom will host a VOQUEZNA product theater presentation on May 4 at DDW 2026 and exhibit at booth 2511, highlighting three poster presentations of clinical and real-world GI data. VOQUEZNA, approved for erosive and non-erosive GERD and H. pylori infection, aims to support market adoption and scientific engagement.
1. DDW Participation and Product Theater
Phathom will engage with the GI community at Digestive Disease Week 2026, May 2–5 in Chicago, with a booth presence at number 2511. A VOQUEZNA product theater presentation is scheduled for May 4 at 12:00 PM CDT to showcase the drug’s clinical profile and applications.
2. Clinical and Real-World Data Presentations
The company will present three poster sessions featuring new clinical trial results and real-world evidence on VOQUEZNA’s efficacy and safety in both erosive and non-erosive GERD, as well as H. pylori infection treatment in combination regimens.
3. Strategic Implications for VOQUEZNA Adoption
Showcasing VOQUEZNA at a leading GI conference is intended to strengthen scientific engagement, validate treatment benefits among key opinion leaders, and drive physician awareness to support broader market uptake.